Woodline Partners’s CASI Pharmaceuticals CASI Stock Holding History

Woodline Partners’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-133,406	Closed	-$113K	–	1045
2025 Q4	$113K	Sell	133,406 -32,234	-19%	-$41.7K	﹤0.01%	1009
2025 Q3	$275K	Hold	165,640	–	–	﹤0.01%	858
2025 Q2	$195K	Buy	165,640 +1,275	+0.8%	+$2.34K	﹤0.01%	904
2025 Q1	$355K	Buy	164,365 +64,675	+65%	+$158K	﹤0.01%	849
2024 Q4	$282K	Buy	99,690 +69,158	+227%	+$328K	﹤0.01%	893
2024 Q3	$188K	Buy	+30,532	New	+$197K	﹤0.01%	578

Other funds holding CASI

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Woodline Partners's CASI Position: Q1 2026 in Review

Woodline Partners sold out of CASI Pharmaceuticals (CASI) in Q1 2026, closing a stake of 133,406 shares — an estimated $113K sold.

Woodline Partners first reported a position in CASI in Q3 2024 and held it in 6 quarters. The position peaked at $355K in Q1 2025. 1 fund tracked by Wall St. Rank holds CASI as of Q1 2026.

Woodline Partners reported no remaining CASI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Woodline Partners sold 133,406 CASI Pharmaceuticals shares in Q1 2026, an estimated $113K.
Woodline Partners first reported a position in CASI Pharmaceuticals in Q3 2024 and held it in 6 quarters.
Woodline Partners's CASI Pharmaceuticals position peaked at $355K in Q1 2025.
1 fund tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.